Coronavirus Antiviral Research Database

The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.

冠状病毒抗病毒研究数据库旨在加速新型冠状病毒（SARS-CoV-2）抗病毒疗法的开发进程。该数据库将有助于全球冠状病毒药物研发工作的推进，具体表现在：（1）推动实验结果的统一报告，以便于不同候选抗病毒药物的相互比较；（2）识别冠状病毒抗病毒药物研发中的研究空白；（3）协助科学家、临床研究人员、公共卫生官员和资助机构优先考虑最有潜力的化合物和重新定位的药物以进行进一步开发；（4）为公众提供客观、基于证据的信息来源；（5）为寻求并欢迎反馈的冠状病毒研究人员提供一个思想交流的平台。通过全面审查所有已发表的实验室、动物模型和临床数据关于潜在冠状病毒疗法的研究，数据库降低了有希望的疗法方法被忽视的可能性。此外，通过使比较竞争性治疗策略相关联的底层数据成为可能，利益相关者将能够更好地优先考虑最有潜力的抗冠状病毒化合物以进行进一步开发。